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Abstract 
AIM: To compare the frequency of echocardiographic changes in patients with chronic obstructive pulmonary 
disease (COPD) and non-COPD controls and to assess their relation to the level of airflow limitation.  
METHODS: Study population included 120 subjects divided into two groups. Group 1 included 60 patients with 
COPD (52 male and 8 females, aged 40 to 80 years) initially diagnosed according to the actual recommendations. 
Group 2 included 60 subjects in whom COPD was excluded serving as a control. The study protocol consisted of 
completion of a questionnaire, pulmonary evaluation (dyspnea severity assessment, baseline and post-
bronchodilator spirometry, gas analyses, and chest X-ray) and two dimensional (2D) Doppler echocardiography. 
RESULTS: We found significantly higher mean right ventricle end-diastolic dimension (RVEDd) in COPD patients 
as compared to its dimension in controls (28.0 ± 4.8 mm vs. 24.4 ± 4.3 mm; P = 0.0000). Pulmonary hypertension 
(PH) was more frequent in COPD patients than in controls (33.3% vs. 0%; P = 0.0004) showing a linear 
relationship with the severity of airflow limitation. The mean value of left ventricular ejection fraction (LVEF%) was 
significantly lower in COPD patients than its mean value in controls (57.4 ± 6.9% vs 64.8 ± 2.7%; P = 0.0000) with 
no correlation with severity of airflow limitation.  
CONCLUSION: Frequency of echocardiographic changes in COPD patients was significantly higher as compared 
to their frequency in controls in the most cases being significantly associated with the severity of airflow limitation. 
Echocardiography enables early, noninvasive, and accurate diagnosis of cardiac changes in COPD patients 
giving time for early intervention. 
 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) is accompanied by comorbidities which have 
a significant impact on its prognosis. Furthermore, 
cardiovascular comorbidities are considered as a 
major cause for hospitalization and mortality in COPD 
patients [1], [2], [3], [4], [5], [6]. COPD affects 
pulmonary blood vessels, right ventricle and left 
ventricle leading to right ventricular dysfunction, left 
ventricular dysfunction, pulmonary hypertension (PH) 
and cor pulmonale [7]. 
COPD patients have two to three-fold 
increased risk for hospitalisation due to cardiovascular 
morbidity compared to patients without COPD [8]. 
Also, 20-30% of all patients with chronic heart failure 
have COPD [9], [10]. Shortness of breath and reduced 
effort tolerance is present in both diseases, so cardiac 
failure in COPD often remains unrecognised and 
symptoms are attributed to COPD exacerbations. The 
reason is that two dimensional (2D) Doppler 
echocardiography as a diagnostic method for heart 
failure is not implemented in primary care and is not a 
standard diagnostic procedure for pulmonologists 
controlling these patients [9], [11]. Mortality from 
cardiovascular diseases (CVD) is about 30% and in 
patients with mild and moderate COPD, the most 
common cause of hospitalisation and mortality is 
cardiovascular disease. Lung Health Study showed 
that reduction of 10% of forced expiratory volume in 
one second (FEV1) value in the patients with mild and 
moderate COPD increases the risk of fatal 
cardiovascular events up to 30% and of non-fatal 
coronary events up to 20% [12]. As it was mentioned 
in the Towards a Revolution in COPD Health 
(TORCH) study, in patients with severe COPD, CVD 
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was less significant for morbidity and mortality 
whereas respiratory failure was the predominant 
factor [13]. Prevalence of pulmonary hypertension 
(PH) in COPD patients is estimated to 20-30% [4]. PH 
in COPD patients usually is mild to moderate with 
mean systolic pulmonary arterial pressure (sPAP) in 
the stable disease of 20-35 mmHg. Only 5-10% of 
patients with severe COPD have severe PH [14], [15]. 
As it was found in the National Emphysema 
Treatment Trial, 90.8% of COPD patients had sPAP 
higher than 20 mmHg and less than 5% had sPAP 
higher than 35 mmHg [16]. sPAP in COPD patients 
usually increases slowly, approximately 0.4-0.6 mmHg 
per year [17], [18]. 
We aimed to compare the frequency of 
echocardiographic changes in patients with chronic 
obstructive pulmonary disease (COPD) and non-
COPD controls and to assess their relation to the level 
of airflow limitation. 
 
 
Material and Methods 
 
Study design and setting 
Frequency and severity of echocardiographic 
changes registered by 2D Doppler echocardiography 
in initially diagnosed COPD patients and non-COPD 
controls were compared in cross-sectional analysis. 
The study was conducted at the General Hospital “8-
th September”, Skopje, in the period January – May 
2018 as a continuum of our investigation of the impact 
of cardiovascular comorbidities on COPD (19). The 
study was approved by the Ethics Committee of the 
Medical Faculty at University “Sts.Cyril and 
Methodius”, Skopje (03-2237/5/21.05.2018) [19]. 
 
Study population 
The study population consisted of 120 
subjects divided into two groups. Group 1 included 60 
patients with newly diagnosed COPD following the 
actual Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) criteria. Also, 60 subjects in whom 
COPD was excluded served as a control (Group 2). 
Non-COPD subjects were matched to COPD patients 
by sex, age, body mass index (BMI), and smoking 
status. Written informed consent was given by all 
subjects before entering the study. 
Inclusion and exclusion criteria for Group 1 
and Group 2 are explained in our article on carotid 
artery disease, and lower extremities artery disease in 
patients with COPD published previously [19]. 
 
Study protocol 
The study workup included completion of a 
questionnaire, as well as pulmonary and 
echocardiographic evaluation. 
 
Questionnaire 
The interviewer-led questionnaire consisted of 
four parts, including questions on demographics, 
smoking history, respiratory and other symptoms in 
the last 12 months, as well as medical history and 
medication use. 
The Body Mass Index (BMI) as a measure of 
body fat based on height and weight that applies to 
adult population was calculated by BMI calculator [20]. 
Study subjects were classified by their 
smoking status according to the World Health 
Organization (WHO) recommendations [21]. 
Respiratory symptoms in the last 12 months, 
i.e. cough, phlegm, dyspnea, wheezing, and chest 
tightness, were documented by the European 
Community for Coal and Steel questionnaire (ECCS-
87), and the European Community Respiratory Health 
Survey (ECRHS) questionnaire [22], [23]. 
 
Pulmonary evaluation 
The pulmonary evaluation included: dyspnea 
severity assessment, pre- and post-bronchodilator 
spirometry, arterial gas analysis, and chest X-ray. 
Assessment of the degree of dyspnea was 
done using the British Medical Council Dyspnea Scale 
[24]. 
Pre-bronchodilator (baseline) spirometry 
included measures of forced vital capacity (FVC), 
FEV1, FEV1/FVC, and maximal expiratory flow at 75%, 
50%, 25%, and 25-75% of FVC (MEF75, MEF50, 
MEF25, and MEF25-75, respectively) by electronic 
spirometer Spirobank G USB Spirometer (Medical 
International Research, Roma, Italy) with recording 
the best result from three measurements the FEV1 
values of which were within 5% of each other. The 
results of measurements were expressed as 
percentages of the predicted values following the 
actual recommendations of the European Respiratory 
Society (ERS) and ATS. Post-bronchodilator 
spirometry was performed 20 minutes after 
administration of 400 g salbutamol by metered-dose 
inhaler through the spacer. Fixed airflow narrowing 
was considered if post-bronchodilator FEV1/FVC value 
remained less than 0.70. The degree of FEV1 
reversibility was expressed as % FEV1 reversibility 
([post-bronchodilator FEV1 – pre-bronchodilator 
FEV1]/pre-bronchodilator FEV1 x 100). Significant 
FEV1 improvement (a change of more than 12% and 
more than 200 mL) in the presence of fixed airflow 
limitation did not negate a diagnosis of COPD [25]. 
The diagnosis of COPD was established 
according to the actual GOLD recommendations, i.e., 
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COPD was considered by the presence of persistent 
airflow limitation, i.e. a post-bronchodilator FEV1/FVC 
value less than 0.70, in the subjects who had 
dyspnea, chronic cough or sputum production, and a 
history of exposure to risk factors for the disease 
(noxious particles and gases, i.e. tobacco smoke, 
smoke from home cooking and heating fuels, and/or 
occupational dusts and chemicals). Also, based on 
the level of the airflow limitation, the COPD severity 
was classified as mild, moderate, severe, and very 
severe (GOLD 1, GOLD 2, GOLD 3, and GOLD 4, 
respectively) [26]. 
Values of the arterial blood gases were 
measured using the SIEMENS RAPIDPOINT 405 
System (Siemens Healthineers, Australia). 
 
Cardiovascular evaluation 
Resting 2D Doppler Echocardiography was 
performed by a cardiologist using General Electric 
Vivid 7, according to the recommendations of the 
American Heart Association (AHA). Measured 
parameters included: left ventricular end-diastolic 
dimension (LVEDd), left ventricular end-systolic 
dimension (LVEDs), left atrial dimension (LA), left 
ventricular ejection fraction (LVEF %) by Teischoltz, 
interventricular septum (IVS), right ventricular end-
diastolic dimension (RVEDd), right atrial dimension 
(RA), estimation of left ventricular diastolic 
dysfunction, measurement of systolic pressure in 
pulmonary artery (sPAP), wall abnormalities in right 
ventricle, and mitral, aortic, tricuspid and pulmonary 
valvular evaluation. Right ventricular dilation is 
present when RVEDd exceeded the normal range of 
0.9-2.6 cm. Right ventricular systolic dysfunction was 
present when it was hypokinetic. E/A, i.e. diastolic 
filling of the left ventricle, was classified initially based 
on the peak mitral flow velocity of the early rapid filling 
wave (E) and the peak velocity of the late filling wave 
caused by atrial contraction (A). In normal subjects, 
LV elastic recoil is vigorous because of normal 
myocardial relaxation. Therefore, more filling is 
completed during early diastolic, so LVEDd is present 
when E/A value is less than 1.3 (age group 45-49 
years), less than 1.2 (age group 50-59 years), less 
than 1.0 (age group 60-69 years), and less than 0.8 
(age group aged equal or more than 70 years) (30). 
Pulmonary hypertension was defined as a sPAP value 
equal to or higher than 30 mmHg. According to the 
severity degree, PH is classified as mild (sPAP = 30-
50 mmHg), moderate (sPAP = 50-70 mmHg) and 
severe (sPAP > 70 mmHg) [27], [28]. 
 
Statistical analysis 
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 17.0 for Windows. Continuous variables were 
expressed as mean values with standard deviation 
(SD), and the nominal variables as numbers and 
percentages. Analyses of the data included testing the 
differences in prevalence, comparison of the means, 
and testing the association mentioned above. A P-
value of less than 0.05 was considered as statistically 
significant.  
 
 
Results 
 
Characteristics of the study subjects were 
similar in both EG and CG with the exception of the 
mean values of spirometric parameters which were 
significantly lower in COPD patients than in controls. 
Table 1: Characteristics of the study subjects 
Characteristic 
Group 1 
(n = 60) 
Group 2 
(n = 60) 
Sex 
M 
F 
 
52 (86.7%) 
8 (13.3%) 
 
47 (78.3%) 
13 (21.6%) 
Mean age (yrs) 
M 
F 
 
65.9 ± 7.5 
67.9 ± 6.1 
 
64.3 ± 8.1 
65.3 ± 7.4 
Smoking status 
Active smokers 
Ex-smokers 
Pack-year smoked 
 
5 (58.3%) 
25 (41.7%) 
66.1 ± 25.8 
 
37 (61.6%) 
23 (38.3%) 
64.8 ± 21.5 
Mean BMI value 25.8 ± 4.9 25.9 ± 3.1 
Mean baseline values  
FVC (% pred) 
FEV1 ((% pred) 
FEV1/FVC ratio 
 
78.8 ± 12.3 
47.5 ± 17.9 
0.6 ± 0.07 
 
113.1 ± 19.7 
90.4 ± 15.2 
0.8 ± 0.04 
M: male; F: female; yrs: years; BMI: body mass index; FVC: forced vital capacity; FEV1: 
forced expiratory volume in one second; % pred: percentage of the predicted value. 
 
Distribution of the COPD patients by severity 
of the disease based on the degree of airflow 
limitation in mild, moderate, severe, and very severe 
form was 6.7% (4/60) patients), 35% (21/60), 36.7% 
(22/60), and 21.7% (13/60), respectively. 
Table 2: Echocardiographic changes in COPD patients 
classified by the level of airflow limitation 
Echocardiography 
characteristic of all 
COPD patients 
(n = 60) 
GOLD 1 
FEV1 ≥ 80% 
pred. 
(n = 4) 
GOLD 2 
FEV1 = 50%-
79% pred. 
(n = 21) 
GOLD 3 
FEV1 = 30%-
49% pred. 
(n = 22) 
GOLD 4 
FEV1 < 30 % 
pred. 
(n = 13) 
Normal findings 0 (0%) 0 (0%) 2 (9.5%) 2 (50%) 
Mild PH 0 (0%) 3 (14.3%) 6 (27.3%) 4 (30.8%) 
Moderate PH 0 (0%) 1 (4.8%) 1 (4.5%) 2 (15.4%) 
Severe PH 0 (0%) 1 (4.8%) 1 (4.5%) 1 (7.7%) 
Mild TR 2 (50%) 10 (47.6%) 12 (54.5%) 6 (46.1%) 
Moderate TR 0 (0%) 0 (0%) 3 (13.6%) 4 (30.8%) 
Severe TR 0 (0%) 1 (4.8%) 2 (9.1%) 0 (0%) 
Mild PR 0 (0%) 2 (9.5%) 1 (4.5%) 1 (7.7%) 
RVEDd > 26mm 1 (25%) 10 (47.6%) 13 (59.1%) 7 (53.9%) 
Enlargement of RA 0 (0%) 1 (4.8%) 2 (9.1%) 2 (15.4%) 
Mild MR 2 (50%) 9 (42.9%) 10 (45.4%) 6 (46.1%) 
Mild AR 0 (0%) 3 (14.3%) 6 (27.3%) 3 (23.1%) 
Mild MS 0 (0%) 1 (4.8%) 1 (4.5%) 0 (0%) 
IVS > 12mm 2 (50%) 6 (28.6%) 14 (63.6%) 7 (53.9%) 
LVEDd >56mm 0 (0%) 3 (14.3%) 3 (13.6%) 0 (0%) 
LA > 40mm 2 (50%) 9 (42.9%) 8 (36.4%) 5 (38.5%) 
Concentric hypertrophy 
of LV with diastolic 
dysfunction of the type- 
impaired relaxation 
1 (25%) 3 (14.3%) 12 (54.5%) 3 (23.1%) 
Impaired global systolic 
function of LV 
0 (0%) 3 (14.3%) 2 (9.1%) 0 (0%) 
Abnormal left ventricular 
kinetics 
0 (0%) 4 (19.0%) 3 (13.6%) 0 (0%) 
COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; PH: pulmonary hypertension; TR: tricuspid regurgitation; PR: 
pulmonary regurgitation; RVEDd: right ventricular end-diastolic dimension; RA: right atrial; 
MR: mitral regurgitation; AR: aortic regurgitation; MS: mitral stenosis; IVS: interventricular 
septum; LVEDd: left ventricular end-diastolic dimension; LA: left atrial; LV: left ventricle. 
Registered echocardiographic changes in the 
subjects of Group 1 classified according to the 
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severity of airflow limitation are presented in Table 2. 
The most frequent abnormality of the right heart was 
increased RVEDd, whereas dilated left atrium and left 
ventricular hypertrophy were the most frequent left 
heart abnormalities. Also, TR was the most frequent 
valvular abnormality. 
Comparison of echocardiographic findings 
indicated a significant difference between right heart 
parameters in the Group 1 as compared to their 
values in the Group 2. Also, except interventricular 
septum, there was a significant difference between 
the two groups (Table 3). 
Table 3: Comparison of certain echocardiographic parameters 
in the two groups 
Echocardiographic 
parameter 
Group 1 
(n = 60) 
Group 2 
(n = 60) 
P value 
LA (19.0-40.0 mm) 39.0 ± 5.3 36.4 ± 3.5 P = 0.0019 
LV-s < 39 mm 33.6 ± 6.4 30.7 ± 2.4 P = 0.0013 
RVEDd (7.0-26 mm) 28.0 ± 4.8 24.4 ± 4.3 P = 0.0000 
LVEDd (35.0-56.0 mm) 50.05 ± 5.8 46.2 ± 4.1 P = 0.0000 
IVS (7.0-12 mm) 11.1 ± 1.9 11.4 ± 1.2 P = 0.1032 
LVEF% 57.4 ± 6.9 64.8 ± 2.7 P = 0.0000 
LA: left atrial dimension; LV-s: left ventricular systolic dimension; RVEDd: right ventricular 
end-diastolic dimension; LVEDd: left ventricular end-diastolic dimension; IVS: 
interventricular septum; LVEF%: left ventricle ejection fraction. 
 
As it is mentioned above, the mean value of 
the LVEF% in non-COPD controls was significantly 
higher compared to its value in COPD patients but 
there was no correlation with COPD severity (Table 
4). 
Table 4: LVEF% value about COPD severity 
COPD severity LVEF% value 
GOLD 1 61.3% 
GOLD 2 56.1% 
GOLD 3 57.0% 
GOLD 4 55.6% 
COPD: chronic obstructive pulmonary disease; LVEF%: left ventricle ejection fraction; 
GOLD: Global Initiative for Chronic Obstructive Lung Disease. 
 
Frequency of PH was significantly higher in 
COPD patients compared to its frequency in non-
COPD controls (33.3% vs. 0%; P = 0.0004). 
Frequency of PH proportionally increased with FEV1 
decline (Table 5). 
Table 5: Frequency of PH about the level of airflow limitation 
COPD severity Frequency of PH 
GOLD 1 0% 
GOLD 2 23.8% 
GOLD 3 41.0% 
GOLD 4 46.1% 
COPD: chronic obstructive pulmonary disease; PH: pulmonary hypertension; GOLD: 
Global Initiative for Chronic Obstructive Lung Disease. 
 
 
 
Discussion 
 
Comorbidities such as cardiac disease, 
peripheral vascular disease, hypertension, metabolic 
syndrome, diabetes mellitus, osteoporosis, and 
psychological disorders are commonly presented in 
patients with COPD with great variability in reported 
prevalence. Besides, cardiovascular comorbidities are 
considered as an important cause of mortality in 
COPD patients [5], [6]. 
The present study aimed to compare the 
frequency of echocardiographic changes registered by 
resting 2D transthoracic Doppler echocardiography in 
COPD patients and non-COPD controls and to assess 
their relation to the level of airflow limitation. We 
performed a cross-sectional study including 120 
subjects divided into two groups. The first group 
included 60 initially diagnosed with COPD, whereas 
the second group included an equal number of 
subjects in whom COPD was excluded 
complementary by their demographic characteristics 
to the patients with COPD. Airflow limitation in more 
than half of the newly diagnosed COPD patients was 
assessed as severe or very severe indicating delayed 
recognising of the disease and late-onset of adequate 
treatment. 
Resting 2D Doppler echocardiography was 
done by the same cardiologist and valvular anatomy 
and function, left, and right ventricle size and cardiac 
function were assessed. 
Values of the RV parameters were 
significantly higher in COPD patients. There was a 
high prevalence of PH, right atrial enlargement, RV 
systolic dysfunction and tricuspid regurgitation in 
COPD patients, and their severity increased with 
COPD severity. Cor pulmonale was found in 16.7% of 
our COPD patients which correlates with 17.5% in 
Gupta et al., a study [29]. 
TR peak gradient as a marker for indirect 
evidence of PH was studied in all patients. TR in the 
present study was found in 44.4% of the COPD 
patients, that is less than its frequency in the studies 
performed by Higham et al., (77%) and by Kassim et 
al., (70%) [30], [31]. The difference can be explained 
by several factors like the type of equipment used, the 
experience of the operator, the quality of the image 
obtained or the body habitus. Impairment of RV 
function and alteration of pulmonary blood vessels 
complicate the clinical course of COPD and correlates 
inversely with the survival of these patients [7]. 
LV systolic function was significantly higher in 
non-COPD controls as compared to the COPD 
patients. Frequency of the LV systolic dysfunction was 
5.5% in the COPD patients, that was similar to its 
frequency reported in the Gupta study (7.5%). 
Abnormal LV performance in the patients with COPD 
may be due to hypoxemia, acidosis, concurrent 
coronary artery disease, and ventricular 
interdependence as the RV and LV share a common 
septum [29]. 
Two major factors implicated in the mortality 
of COPD are the severity of PH and the development 
of cor pulmonale. Cor pulmonale reduces the survival 
of up to 30% [32]. Although the true prevalence of PH 
in COPD is still unknown, an elevation of pulmonary 
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arterial pressure is reported in 20-90% of patients 
when measured by right heart catheterisation [29]. 
The level of PH has a prognostic value for COPD 
patients that is demonstrated in several studies. In 
one of them, the 5-year survival rates were 50% in 
patients with mild PH (20-30 mmHg), 30% in those 
with moderate to severe PH (30-50 mmHg), and 0% in 
the small group of patients with severe PH (> 50 
mmHg) [30]. As a conclusion, the high level of PH is 
associated with poor prognosis in COPD patients [7]. 
PH was not detected in any subject from 
Group 2, whereas its frequency among COPD 
patients was 33%. PH frequency reported in the 
studies conducted by Kassim et al., and Rabab et al., 
was 36% and 55.6%, respectively [31], [32]. 
Distribution of PH in patients with moderate, severe, 
and very severe COPD in the present study was 
23.8%, 41% and 46.1%, respectively. Increased PH 
prevalence following increasing level of airflow 
limitation is also reported in the study conducted by 
Gupta & Mann and Rabab i.e. the reported prevalence 
of PH in patients with mild, moderate, severe, and 
very severe COPD was 16.7%, 54.5%, 60.0% and 
83.3%, respectively [29], [33]. 
The findings of this study are subjects of at 
least three limitations. Firstly, the relatively small size 
of the study groups may have implications on data 
obtained and its interpretation. Secondly, the irregular 
distribution of the patients with COPD by the level of 
airflow limitation may also impact data obtained and 
its interpretation. Besides, the distribution of the study 
subjects by sex is also unequal. On the other side, the 
strength of the study is echocardiographic 
assessment in the initially diagnosed COPD patients. 
In conclusion, in a cross-sectional study on 
the frequency of echocardiographic changes in newly 
diagnosed COPD patients and their relation to the 
level of disease severity we found a significantly 
higher prevalence of echocardiographic changes in 
COPD patients than in non-COPD controls which 
were significantly related to the level of airflow 
limitation. Our findings indicated that 
echocardiographic assessment should be a 
constitutive part of a periodic screening of all patients 
with COPD to implement a combined therapeutic 
strategy which should reduce morbidity and mortality 
in these patients. 
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